Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
The Motley Fool April 28, 2005 Stephen D. Simpson	Bristol-Myers: Hang in There Generics are wreaking havoc on growth, but patient investors can pin hopes on drugs now in the pipeline.
Knowledge@Wharton	Bristol-Myers Squibb Illustrates Woes of Ailing Pharmaceutical Industry The once-mighty pharmaceutical industry, for years the nation's most profitable, has begun to show some cracks. But no major U.S. drug maker seems to be facing more problems than Bristol-Myers Squibb.
BusinessWeek February 26, 2007 Arlene Weintraub	The Power Of The Pipeline Bristol-Myers Squibb is beset with troubles, but its new-drug potential makes it a target.
Pharmaceutical Executive January 21, 2014 Tim Powell	Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way?
Pharmaceutical Executive December 1, 2005 Patrick Clinton	PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products.
Pharmaceutical Executive November 1, 2014 Josh Baxt	2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies.
The Motley Fool January 25, 2006 Stephen D. Simpson	Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
The Motley Fool October 28, 2005 Stephen D. Simpson	Bristol-Myers' Bad Mojo The possible loss of the experimental diabetes drug Pargluva is a blow to this pharmaceutical that's already hurting for growth. If you're expecting a near-term bang for your investment buck, this might not be the best destination.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
Pharmaceutical Executive May 1, 2011 Jill Wechsler	Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
Chemistry World April 9, 2015 Emma Stoye	BMS invests in gene therapy Bristol-Myers Squibb has agreed to invest over $100 million in Netherlands-based biotechnology company uniQure, which specializes in gene therapies for cardiovascular diseases.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
Pharmaceutical Executive October 1, 2005 Jill Wechsler	Washington Report: Antivirals: Meeting a World of Need The international fight against AIDS requires drugs -- and policy.
The Motley Fool September 12, 2005 Brian Gorman	Mixed Diagnosis for Bristol-Myers Positive news on two drugs is reason to celebrate, but investors may want to keep their enthusiasm in check.
The Motley Fool September 6, 2005 Stephen D. Simpson	FDA's Eye on 2 Potential Blockbusters This week, FDA advisory panels will consider the marketing approval applications of Exubera, the inhaled insulin from Pfizer/Sanofi/Nektar, and Pargluva, the dual PPAR agonist, taken in pill form, from Bristol-Myers and Merck. Investors, take note.
Chemistry World December 3, 2013 Phillip Broadwith	New wave of hepatitis C drugs hits US shore Johnson & Johnson's hepatitis C drug Olysio (simeprevir) has been approved by the US Food and Drug Administration.
Pharmaceutical Executive February 1, 2014 Stan Bernard	Product Positioning 2.0 Industry and market transformations have dramatically altered when and how products should be positioned for launch
The Motley Fool July 28, 2005 Stephen D. Simpson	Bristol-Myers' Road to Better Health Bristol-Myers looks toward 2007 and a resumption of real growth. For now, things could be a lot worse. At least investors can't say they're not getting paid to be patient.
The Motley Fool September 13, 2006 Brian Lawler	What to Make of Bristol-Myers Take a good look at the industry to try to sort out the meaning of all the news and the rumors. Investing in a company based on a possible buyout is never a good idea when the possibility is based solely on rumors and analyst speculation.
Chemistry World June 5, 2015 Rebecca Trager	BMS sues executive for joining rival company Bristol-Myers Squibb has filed a lawsuit against a former executive who quit suddenly last month to work for a direct competitor, AstraZeneca.
Pharmaceutical Executive September 1, 2006 Kieran Hartsough	Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside.
Chemistry World June 12, 2014 Andy Extance	Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors.
Chemistry World January 11, 2012 Andrew Turley	BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection.
The Motley Fool June 21, 2007 Billy Fisher	A Bull-Run at Bristol The strength of its oncology pipeline sets Bristol-Myers apart from its peers. Regardless of whether the company is ultimately taken over, shareholders are definitely in a better position than they have been in recent years.
The Motley Fool February 1, 2008 Brian Lawler	Credit Crisis Bites Big Pharma Bristol-Myers Squibb takes a $275 million writedown in its investment portfolio for the quarter.
Chemistry World December 20, 2013 Patrick Walter	AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture.
The Motley Fool October 2, 2007 Billy Fisher	Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA.
Chemistry World October 21, 2011 Sarah Houlton	Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns.
Bio-IT World July 2005 Kevin Davies	Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference.
Pharmaceutical Executive February 1, 2007 Bryan Luce	Toolkit: Going Head to Head More and more, drugs both new and old are having to justify their price tags by proving that they're stronger, more effective, safer, or easier to take than the competition.
Chemistry World November 3, 2015 Phillip Broadwith	Bristol-Myers Squibb to buy Cardioxyl for heart drug The deal gives BMS full rights to develop CXL-1427, an experimental drug for acute decompensated heart failure, currently in Phase II clinical trials.
Chemistry World February 2008 Nuala Moran	The Chemistry of Private Equity Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies?
Pharmaceutical Executive December 1, 2012 William Looney	2012: Year of Record The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry for good or bad in the year 2012.
Chemistry World January 11, 2016 Phillip Broadwith	GSK's ViiV to buy HIV drugs from BMS Bristol-Myers Squibb has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology.
Chemistry World August 27, 2014 Phillip Broadwith	Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems.
Chemistry World April 4, 2013 Phillip Broadwith	Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin.
Chemistry World January 21, 2013 Andy Extance	India pushes for emergency drug licenses The Indian government is preparing to grant compulsory licenses allowing three patented cancer drugs to be produced in the country and sold at reduced rates without permission from the patent owners.
Chemistry World April 21, 2010 Sarah Houlton	Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.
Chemistry World July 3, 2012 Andrew Turley	BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs.
Chemistry World October 7, 2015 Phillip Broadwith	Bristol-Myers-Squibb fined for alleged Chinese bribes The US Securities and Exchange Commission has fined New York based pharmaceutical company Bristol-Myers Squibb over $14 million over alleged bribes made to Chinese state owned hospitals.
Chemistry World March 14, 2014 Phillip Broadwith	Bristol-Myers Squibb to close Irish plant BMS tied the closure to 'changing market demand' for its products, along with efforts to optimize its manufacturing network.